All News
Inflammatory bowel disease in spondyloarthritis - does it matter?
Do the clinical features of axSpA patients with and without IBD differ?
In Abstract OP0085 at #EULAR2024, De Hooge M et al presented data from the METEOR cohort that identify clinical differences between these two groups. This will be important in order to stratify the management approach in axSpA patients with or without IBD as the emerging therapies have different effects on EMMs.
Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9
Dr. John Cush RheumNow ( View Tweet)
New hypothesis are explored in #Sjogren
#EULAR2024
CB https://t.co/0glF5BGVO5
Links:
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Major pathogenic characteristics of #Sjogren disease
#EULAR2024
CB https://t.co/3NeBBKIVT4
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Did the patient fail on therapy or are the therapies failing the patient? š¤
Difficult to to manage psoriatic arthritis: A suggested approach
#EULAR2024
NZ https://t.co/lYvXEX7dp3
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
#Editorās #Choice
@MatsJunek
Who #relapses in
#ANCA #vasculitis
In #Pexivas trial
#Renal #failure may be protective from relapses.
Seems to be the case in renal #lupus #GN too~my opinion
?Why š¤·
#EULAR2024 #EULARBEST @ARD_BMJ
@RheumNow @eular_org @ACR_Journals https://t.co/kUD1qjnwqE
Links:
Janet Pope Janetbirdope ( View Tweet)
I was allocated to bring down the warning, & I did apologise up front to both the EMA and Janet #EULAR2024. It's a tough gig regulating impactful medicines with risk-benefit, especially when our world is full of other medicines with risk-benefit trade-offs (like prednisolone). 2/ https://t.co/6YPhYHbhg8
Links:
David Liew drdavidliew ( View Tweet)
So how do we get from slightly increased numbers of uncommon events in a single study (ORAL Surveillance)?
Regulators think differently to us, which partly is the difficulty of a restrictive warning.
So being the Aussie I am, I asked - does it pass the 'pub test'? 4/ #EULAR2024 https://t.co/Ih9H87wH22
Links:
David Liew drdavidliew ( View Tweet)
Having said that, the EMA warning has elements making it extremely tough:
- still very broad criteria that capture 80% of people who were starting JAKi
- the need for "no suitable treatment alternatives" before using a JAKi, right across all diseases (not just RA) 3/ #EULAR2024 https://t.co/IsrYO7qzqM
Links:
David Liew drdavidliew ( View Tweet)
So I think there is plenty we could do instead.
better regulation
better risk stratification
better counselling
better risk factor management
(and definitely read this if you want to be a good clinician: https://t.co/RA6ktQB7gm)
18/ #EULAR2024 https://t.co/bC5nmi8SoM
Links:
- The Art of Communicating Risk and Benefit to Promote Shared DecisionāMaking, Inā¦
- https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
- https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
- https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
- https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
David Liew drdavidliew ( View Tweet)
My friend the late, great @philipcrobinson and I wrote @TheLancetRheum about what we could learn from COVID about preventative medicine.
https://t.co/55j8rduvyn
It's worth us thinking how we can do better by our patients.
18/ #EULAR2024 https://t.co/zlDKYngsu0
Links:
David Liew drdavidliew ( View Tweet)
Here's my 'pub test' for whether the warning is appropriate. And, debate aside, I do believe that it behoves any regulator to consider the unintended consequences of their regulation, because regulation has real consequences. 5/ #EULAR2024 https://t.co/aurbAwgl9P
David Liew drdavidliew ( View Tweet)
The original direct comparison study! https://t.co/hqrPKfNW1y
Bella Mehta bella_mehta ( View Tweet)
Computer vision/ image analysis is performing very well in rheumatology and can extend help to low resource settings easily! #EULAR2024 https://t.co/8doM7foriM
Bella Mehta bella_mehta ( View Tweet)
SLE RPI may be used more frequently
and can connect the digital dots! @RheumNow https://t.co/UdVIyZJhJV
Bella Mehta bella_mehta ( View Tweet)
Deep learning models are detecting CPPD in radiographs pretty well!! Abst#0112 #EULAR2024 presented by @ThomasHugle ...@RheumNow https://t.co/9z3VVbyyh0
Links:
Bella Mehta bella_mehta ( View Tweet)
Day 1 #EULAR2024 Do you want to learn about the effectiveness of rituximab for systemic features of #Sjogren and potential strategies to overcome non-response? Please come to my talk today (OP0076) and say hi šš¼ š Room C7 at 1720 hr CET @RheumNow https://t.co/uo2ivC5AeY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0077 Please find an interview with my dear colleague @edvital on the importance of achieving and sustaining B cell depletion for improved clinical response in #lupus #SLE @RheumNow
https://t.co/4rTtFWxSvs https://t.co/4esoFTsgzC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)